Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease

Childhood interstitial lung disease (chILD) comprises >200 rare respiratory disorders, with no currently approved therapies and variable prognosis. Nintedanib reduces the rate of forced vital capacity (FVC) decline in adults with progressive fibrosing interstitial lung diseases (ILDs). We present...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:ERJ Open Res
Autori principali: Deterding, Robin, Griese, Matthias, Deutsch, Gail, Warburton, David, DeBoer, Emily M., Cunningham, Steven, Clement, Annick, Schwerk, Nicolaus, Flaherty, Kevin R., Brown, Kevin K., Voss, Florian, Schmid, Ulrike, Schlenker-Herceg, Rozsa, Verri, Daniela, Dumistracel, Mihaela, Schiwek, Marilisa, Stowasser, Susanne, Tetzlaff, Kay, Clerisme-Beaty, Emmanuelle, Young, Lisa R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: European Respiratory Society 2021
Soggetti:
Study Protocols
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8215331/
https://ncbi.nlm.nih.gov/pubmed/34164554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00805-2020
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi